Table 1.

Completed clinical trials.

CDK Inhibitor	NCT Number	Conditions	Interventions	Phases	Enrollment	Start Date	Comp. Date
Palbociclib
		EBrCa	Palbociclib	Phase 2	132	01/01/14	01/01/16
		BrNeo	Palbociclib letrozole	Phase 2	61	10/19/12	10/25/18
		BrCa	Palbociclib  Anastrozole  Letrozole  Exemestane  Fulvestrant	Phase 2	115	10/01/12	02/09/17
		Healthy	Palbociclib	Phase 1	24	05/01/12	11/01/12
		BrCa	Palbociclib letrozole	Phase 2	177	09/15/08	12/20/17
		Neo	Palbociclib	Phase 1	74	09/01/04	12/01/14
Ribociclib
		BrCa	Ribociclib BYL719 Fulvestrant BKM120	Phase 1/2	70	05/19/14	04/17/18
		CDK4/6 Ac.	Ribociclib	Phase 2	106	08/25/14	01/17/18
		AST	Ribociclib	Phase 1	156	12/21/10	03/09/17
		MBC	Ribociclib Buparlisib Letrozole	Phase 1	13	06/27/14	10/26/16
Abemaciclib
		BrCa	Abemaciclib	Phase 2	101	03/16/16	02/02/18
		MBC	Abemaciclib	Phase 2	132	06/10/14	10/22/18
		BrCa HR+	Abemaciclib Loperamide Anastrozole	Phase 2	224	08/01/15	02/12/18

BrCa: breast cancer; EBrCa: Early breast cancer; MBC: Metastatic breast cancer; CDK4/6 Ac.: CDK4/6 Activated pathway; BrCa ERα⁺: Breast cancer hormone receptor positive.